Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello hello. Today, we learn more about AlphaGenome’s efforts to unravel DNA dark matter, read about a new AI-driven biotech backed by former Google CEO Eric Schmidt, and more.
The need-to-know this morning:
Sanofi and Roche reported fourth-quarter and full-year 2025 earnings.
Summit Therapeutics said the FDA accepted its application seeking approval of its PD-1/VEGF antibody ivonescimab to treat non-small cell lung cancer. A decision date is expected on Nov. 14. Â
AstraZeneca plans to invest $15 billion in China through 2030 to expand its manufacturing and R&D capabilities.
Eric Schmidt-backed Hologen chases big AI bet
Hologen, a secretive AI biotech co-founded by former Google CEO Eric Schmidt, is seeking to raise $150 million in a Series A round at an alleged $850 million valuation, STAT’s Brittany Trang has learned. The company is pitching investors on technology it claims can “de-risk” late-stage clinical trials by modeling biological heterogeneity that obscures true drug effects.Continue to STAT+ to read the full story…